President Giorgio Ventura Calls for Calabria to Take Action on Life-Saving Diabetes Drug
President Giorgio Ventura of Onmic Calabria has issued a pressing call for action in response to a recent decision by the Italian Medicines Agency (AIFA) to reclassify the drug Glucagon in nasal spray form. The move, which would place the drug in a payment category, has raised concerns about the potential impact on patients suffering from severe forms of diabetes.
In a press note, President Ventura expressed dismay over the decision, highlighting the potential consequences for patients, particularly children, who rely on the drug for insulin-dependent diabetes. He noted that the intramuscular version of the drug remains reimbursable, but the decision to reclassify the nasal spray version has raised concerns about accessibility and affordability.
President Ventura acknowledged the efforts of national associations of diabetic patients in mobilizing support and advocating for the drug to be returned to the exempt range. He also highlighted the proactive response of regions such as Emilia Romagna and Puglia, which have taken on the cost of the drug to ensure that patients are not left without access to this essential medication.
The president emphasized the practicality of the nasal spray form of the drug, particularly for children, and underscored the need for swift action from other regions to prevent discrimination within the healthcare sector. He called on the Calabria Region to intervene promptly to address the pricing issue, stating that the cost of the drug should not serve as a barrier for patients in need.
President Ventura’s call to action underscores the importance of ensuring equitable access to life-saving medications for all patients, regardless of their geographical location or economic status. As discussions continue regarding the reclassification of Glucagon in nasal spray form, the need for prompt and decisive action to support patients with severe forms of diabetes cannot be overstated.